DelveInsight launched a new report on Acute Myeloid leukemia Epidemiology Forecast, 2030.
Acute Myeloid leukemia (AML) is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word “acute” in acute Myeloid leukemia denotes the disease’s rapid progression. It’s called Myeloid leukemia because it affects a group of white blood cells called the myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells, and platelets.
Acute Myeloid leukemia is also known as acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia.
DelveInsight’s ‘Acute Myeloid leukemia Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Acute Myeloid leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Acute Myeloid leukemia Epidemiology Report:
Acute Myeloid leukemia accounts for <3% of all cancers, and 25% of all leukemia in adults. Worldwide, the incidence of Acute Myeloid leukemia was reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years.
The incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people aged
The Surveillance has reported an Acute Myeloid leukemia incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%.
Visit for more @ Acute Myeloid leukemia Epidemiology Insights
Scope of the Acute Myeloid leukemia Epidemiology report:
The Acute Myeloid leukemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
The Acute Myeloid leukemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Acute Myeloid leukemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Acute Myeloid leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Acute Myeloid leukemia
The report provides the segmentation of the Acute Myeloid leukemia epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Acute Myeloid leukemia
3. Acute Myeloid leukemia Epidemiology Overview at a Glance
4. Acute Myeloid leukemia: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Acute Myeloid leukemia
9. DelveInsight Capabilities
11. About DelveInsight
DelveInsight’s ‘Acute Myeloid leukemia-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
“Acute Myeloid leukemia Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Myeloid leukemia market. A detailed picture of the Acute Myeloid leukemia pipeline landscape is provided, which includes the disease overview and Acute Myeloid leukemia treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States